Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 14/20 | 1.00 |
| ▸ | BRD4 | O60885 | 14/20 | 0.64 |
| ▸ | MAOA | P21397 | 4/20 | 0.57 |
| ▸ | MAOB | P27338 | 4/20 | 0.57 |
| ▸ | EP300 | Q09472 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4911648 | 1.00 | CREBBP (1.00) | CREBBPBRD4MAOAMAOBEP300 | |
| SCHEMBL17680969 | 0.85 | CREBBP (0.74) | CREBBPBRD4MAOAMAOB | |
| SCHEMBL31444075 | 0.81 | CREBBP (0.67) | CREBBPBRD4MAOAMAOB | |
| SCHEMBL28923896 | 0.81 | CREBBP (0.67) | CREBBPBRD4MAOAMAOB | |
| SCHEMBL19518160 | 0.79 | CREBBP (0.80) | CREBBPBRD4MAOAMAOB | |
| SCHEMBL17673304 | 0.79 | CREBBP (0.80) | CREBBPBRD4MAOAMAOB | |
| SCHEMBL4912276 | 0.79 | CREBBP (0.65) | CREBBPBRD4MAOAMAOB | |
| SCHEMBL17680707 | 0.78 | CREBBP (1.00) | CREBBPBRD4 | |
| SCHEMBL17680476 | 0.78 | CREBBP (1.00) | CREBBPBRD4 | |
| SCHEMBL22368640 | 0.78 | CREBBP (1.00) | CREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204360-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3204360-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10206931-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| WO-2016055028-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, CREBBP, HDAC1 | CREBBP 2/4885BRD4 18/4885MAOA 3792/4885 |
| US-10206931-B2 | Therapeutic compounds and uses thereof | EP300, CREBBP, HDAC1 | CREBBP 2/4885BRD4 18/4885MAOA 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.